HER2阳性转移性乳腺癌的治疗策略分析.pptVIP

谢 谢！ 放映结束 感谢各位批评指导！ 让我们共同进步 * * * Reference Dawood SS et al. J Clin Oncol 2010 28: 92-98. Reprinted with permission. ?2008 American Society of Clinical Oncology. All rights reserved. * * 99 * * * 【H审核】 单用多西紫杉醇组患者部分交叉使用了赫赛汀?（至少48%），这些患者比没有交叉使用赫赛汀?的患者生存期更长。这些资料提示使用赫赛汀?比单用化疗更能改善患者生存期，提前使用赫赛汀?较化疗后续贯使用赫赛汀?获益更多 * Slide 9 The Andersson study is a prospective phase III, multicenter, randomized trial that was designed to evaluate the 有效性 and safety of NVB i.v. plus 曲妥珠单抗 as first-line regimen in patients with HER2 阳性. Patients were randomized to receive either NVB D1, D8 + 曲妥珠单抗 or 多西他赛 D1 plus 曲妥珠单抗